Robert Gardner Harrison Sells 14,209 Shares of Sera Prognostics, Inc. (NASDAQ:SERA) Stock

Sera Prognostics, Inc. (NASDAQ:SERA) insider Robert Gardner Harrison sold 14,209 shares of the stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $7.39, for a total value of $105,004.51. Following the sale, the insider now directly owns 116,837 shares of the company’s stock, valued at $863,425.43. The trade was a 10.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Robert Gardner Harrison also recently made the following trade(s):

• On Monday, January 13th, Robert Gardner Harrison sold 2,264 shares of Sera Prognostics stock. The shares were sold at an average price of $6.47, for a total value of $14,648.08.

Sera Prognostics Price Performance

NASDAQ SERA opened at $6.61 on Thursday. The business’s fifty day moving average is $7.44 and its 200-day moving average is $7.31. The stock has a market capitalization of $223.23 million, a price-to-earnings ratio of -6.68 and a beta of 0.86. Sera Prognostics, Inc. has a one year low of $4.98 and a one year high of $12.35.

Sera Prognostics (NASDAQ:SERA) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.09 million. During the same quarter last year, the company posted ($0.23) earnings per share. Research analysts expect that Sera Prognostics, Inc. will post -0.96 EPS for the current fiscal year.

Hedge Funds Weigh In On Sera Prognostics

Several institutional investors have recently bought and sold shares of SERA. Sanders Morris Harris LLC raised its stake in shares of Sera Prognostics by 165.7% in the fourth quarter. Sanders Morris Harris LLC now owns 90,600 shares of the company’s stock valued at $725,000 after buying an additional 56,500 shares during the period. Pallas Capital Advisors LLC bought a new stake in Sera Prognostics in the 4th quarter valued at about $113,000. JPMorgan Chase & Co. lifted its holdings in Sera Prognostics by 7,357.8% during the third quarter. JPMorgan Chase & Co. now owns 884,867 shares of the company’s stock valued at $6,902,000 after purchasing an additional 873,002 shares during the last quarter. Barclays PLC lifted its holdings in Sera Prognostics by 321.6% during the third quarter. Barclays PLC now owns 39,450 shares of the company’s stock valued at $308,000 after purchasing an additional 30,093 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Sera Prognostics by 8.9% during the third quarter. Geode Capital Management LLC now owns 586,837 shares of the company’s stock worth $4,578,000 after purchasing an additional 47,969 shares during the period. Hedge funds and other institutional investors own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.